The AFAP1L2 (Actin Filament-Associated Protein 1-Like 2) antibody is a tool used to detect and study the AFAP1L2 protein, a member of the AFAP family of scaffolding proteins. AFAP1L2 contains conserved domains, including Src homology 3 (SH3) and pleckstrin homology (PH) domains, which mediate interactions with signaling molecules and cytoskeletal components. It regulates actin dynamics and cellular processes such as migration, adhesion, and membrane protrusion by linking signaling pathways to the actin cytoskeleton.
Research suggests AFAP1L2 may play roles in cancer progression, particularly in tumor invasion and metastasis, due to its influence on cell motility. It has been studied in cancers like breast, lung, and colorectal carcinomas, where altered expression correlates with clinical outcomes. The antibody is utilized in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to assess protein localization, expression levels, and interactions in cellular or tissue samples.
Despite its potential relevance, AFAP1L2 remains less characterized compared to other AFAP family members (e.g., AFAP1). Further studies are needed to clarify its specific mechanisms, post-translational modifications, and therapeutic implications. The AFAP1L2 antibody thus serves as a critical reagent for exploring its biological functions and pathological roles.